Skip to main content

Table 1 Patient characteristics according to absolute lymphocyte count

From: Lymphopenia is an important prognostic factor in peripheral T-cell lymphoma (NOS) treated with anthracycline-containing chemotherapy

  High ALC
(N= 82)
Low ALC
(N= 36)
P-value
Age    
   < 60 vs. ≥ 60 years 51/31 21/15 0.692
Gender    
   Male vs. Female 55/27 24/12 0.966
Performance status    
   0-1 vs. 2-4 74/8 30/6 0.355
B symptom    
   Present vs. Absent 21/61 11/25 0.578
Stage    
   1-2 vs. 3-4 31/51 8/28 0.098
Extranodal involvement    
   0-1 vs. ≥ 2 62/20 21/15 0.059
Bone marrow involvement    
   Positive vs. Negative 21/61 12/24 0.389
LDH    
   Normal vs. Elevated 45/37 12/24 0.031
IPI    
   L, LI vs. HI, H 57/25 18/18 0.043
PIT    
   Group 1-2 vs. 3-4 57/25 16/20 0.010
CR    
   CR vs. non-CR 42/37 14/12 0.952
Response (≥ PR)    
   Responder vs. Non-responder 61/18 17/9 0.231
TRM during the 1st line chemotherapy    
   Yes vs. No 4/78 9/27 0.003
Cycles of 1st line Chemotherapy    
   Median, range 6 (1-8) 3 (1-9) 0.007
  1. LDH, lactate dehydrogenase; IPI, International Prognostic Index; L, low; LI, low-intermediate; HI, high-intermediate; H, high; PIT, Prognostic Index for peripheral T-cell lymphoma; CR, complete response; PR, partial response; TRM, treatment related mortality; ALC, absolute lymphocyte count.